共 69 条
[1]
Estey EH(2012)How to manage high-risk acute myeloid leukemia Leukemia 26 861-869
[2]
Blum W(2010)Dose escalation of lenalidomide in relapsed or refractory acute leukemias J Clin Oncol 28 4919-4925
[3]
Klisovic RB(2011)A phase II study of high dose lenalidomide as initial therapy for older patients with acute myeloid leukemia Blood 117 1828-1833
[4]
Becker H(2012)Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia Leukemia 26 893-901
[5]
Yang X(2013)Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia Haematologica 98 591-596
[6]
Rozewski DM(2013)A phase I study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML Leukemia 27 725-728
[7]
Phelps MA(2010)Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood 115 453-474
[8]
Fehniger TA(2000)Karyotypic analysis predicts outcome of pre-remission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study Blood 96 4075-4083
[9]
Uy GL(2013)Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients Expert Rev Hematol 6 767-784
[10]
Trinkaus K(2012)Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype Leukemia 26 822-824